我国原料药出口市场研究
摘要
自改革开放以来,我国原料药生产得到了迅速发展,中国已成为世界上最大的原料药生产国,在国际医药市场上具有举足轻重的地位。但我国还不是原料药生产和出口强国,在原料药出口贸易中,面临着很多的难题和考验,特别是金融危机的全面爆发后,我国原料药出口开始也随之出现比较明显的下滑趋势。
本文以经济学、国际贸易以及管理学的相关理论为基础,分四个部分进行研究。
第一部分对原料药的国际市场现状和我国原料药出口现状进行分析,其中简单概述了原料药国际需求从无到有从小到大的一般过程,进而从原料药国际市场规模、分布及发展前景等角度分析原料药国际市场现状,介绍了我国原料药生产规模和分布区域及出口地域。
第二部分分析了我国原料药生产和出口优势以及有利影响因素,重点分析了外包业务。
第三部分分析了我国原料药出口所面临的问题和挑战,并着重探讨了我国原料药出口的影响因素,重点分析了技术性贸易壁垒以及中国和印度之间竞争又合作的关系。
第四部分分别从行业、企业以及政府的角度提出了我国原料药行业在出口贸易中应采取的战略对策。
本文试图通过分析和探讨,为原料药市场的资源配置、产业规模、产品结构、经济运行等方面提供具有一定价值的指导,为国内原料药行业中的相关单位,特别是生产出口企业提供一些决策依据,以改善我国原料药出口现状。
Since China embraced the epic reform and opening-up policies, its Active Pharmaceutical Ingredients (abbreviated as API) industry has developed rapidly. China has become the largest API manufacturer, playing a decisive role in international pharmaceutical market. But China is not a strong API manufacturer and export country, and faces with many problems and difficulties in API export trade. Especially after the financial crisis broke out, the exports of Chinese API began to appear obvious decline.
Based on the related theories of Economics, International Trade and Principles of Management, this paper is consists of four parts.
Part one analyzes the current situation of API international market and the current situation of export of Chinese API, briefly outlines the generation and development of the international demand for API, and then analyzes the current situation of API international market according to the API international market scale, distribution and development perspective; and analyzes the current situation of Chinese API process scale, distribution and export regions.
Part two analyzes the strengths of the manufacture and export of Chinese API and the favorable influencing factors, focusing on analysis of outsourcing.
Part three analyses the problems and challenges in the export of Chinese API, elaborating on influencing factors of export of Chinese API, focusing on the analysis of the technical trade barriers and the competition and cooperation relations between China and India.
Part four presents the strategic measures to be taken by Chinese API industry, according to the industry, enterprises and government's points of view.
This paper attempts to provide certain value of the guidance to resources distribution, industry scale, product structure, economic operation in API market according to the above analysis and discussions, and to provide a number of decision-making bases to related departments, particularly to export manufacturer to improve the situations of exports of Chinese API.
本文以经济学、国际贸易以及管理学的相关理论为基础,分四个部分进行研究。
第一部分对原料药的国际市场现状和我国原料药出口现状进行分析,其中简单概述了原料药国际需求从无到有从小到大的一般过程,进而从原料药国际市场规模、分布及发展前景等角度分析原料药国际市场现状,介绍了我国原料药生产规模和分布区域及出口地域。
第二部分分析了我国原料药生产和出口优势以及有利影响因素,重点分析了外包业务。
第三部分分析了我国原料药出口所面临的问题和挑战,并着重探讨了我国原料药出口的影响因素,重点分析了技术性贸易壁垒以及中国和印度之间竞争又合作的关系。
第四部分分别从行业、企业以及政府的角度提出了我国原料药行业在出口贸易中应采取的战略对策。
本文试图通过分析和探讨,为原料药市场的资源配置、产业规模、产品结构、经济运行等方面提供具有一定价值的指导,为国内原料药行业中的相关单位,特别是生产出口企业提供一些决策依据,以改善我国原料药出口现状。
Since China embraced the epic reform and opening-up policies, its Active Pharmaceutical Ingredients (abbreviated as API) industry has developed rapidly. China has become the largest API manufacturer, playing a decisive role in international pharmaceutical market. But China is not a strong API manufacturer and export country, and faces with many problems and difficulties in API export trade. Especially after the financial crisis broke out, the exports of Chinese API began to appear obvious decline.
Based on the related theories of Economics, International Trade and Principles of Management, this paper is consists of four parts.
Part one analyzes the current situation of API international market and the current situation of export of Chinese API, briefly outlines the generation and development of the international demand for API, and then analyzes the current situation of API international market according to the API international market scale, distribution and development perspective; and analyzes the current situation of Chinese API process scale, distribution and export regions.
Part two analyzes the strengths of the manufacture and export of Chinese API and the favorable influencing factors, focusing on analysis of outsourcing.
Part three analyses the problems and challenges in the export of Chinese API, elaborating on influencing factors of export of Chinese API, focusing on the analysis of the technical trade barriers and the competition and cooperation relations between China and India.
Part four presents the strategic measures to be taken by Chinese API industry, according to the industry, enterprises and government's points of view.
This paper attempts to provide certain value of the guidance to resources distribution, industry scale, product structure, economic operation in API market according to the above analysis and discussions, and to provide a number of decision-making bases to related departments, particularly to export manufacturer to improve the situations of exports of Chinese API.
引文
[1]裘真.从第三方服务角度分析中国原料药出口的主要问题和对策研究[D]：[硕士学位论文].济南：山东大学,2008.
[2]伊瑶.2011年全球药品市场将达8800亿美元[N].医药经济报,2010-10-22(A08).
[3]郭晓丹,谈圣采.全球API格局因需求生变[N].医药经济报,2010-01-08(A07).
[4]汤德平,陶锐,项江繁.原料药产业现状和发展趋势[J].上海医药,2007(1)：23.
[5]裘真.我国原料药行业的SWOT分析[J].中国医药技术经济与管理,2008,(1)：38.
[6]谭勇,江沂,金丰杰.中国原料药竞争力对话[N].医药经济报,2003-11-10(A01).
[7]江沂.退税率下调,原料药出口影响有限[N].中国证券报,2007-06-22(B04).
[8]邱家学,李娜.接单外包——中国原料药的新机遇[J].上海医药,2006(10)：446.
[9]马爱霞,韩健.我国原料药出口状况简析[J].昆明理工大学学报(社会科学版),2004,4(4)：2.
[10]曹丽伟.药业产业生产能力国际间转移规律研究[D]：[硕士学位论文].天津：河北工业大学,
[11]. About USP[EB/OL]. http://www.usp.org/aboutUSP/,2010-03-01.
[12]石磊.USP在华设立分支机构,中国原料药出口将获便利[J].上海医药,2007,28(9)：422-423.
[13]朱军.价格战不是主旋律[N].医药经济报,2007-02-28(010).
[14]刘冬冬,孙利华.中印原料药产业竞争力比较研究[J].中国药事,2008,(11)：955.
[15]王承凤.基于节能减排的我国原料药生产企业可持续发展战略研究[D]：[硕士学位论文].沈阳：沈阳药科大学,2008.
[16]顾丽萍,杨潇潇.我国化学原料药的出口前景与对策[J].上海医药,2004,25(1)：15.
[17]赵艳红.我国医药低价出口频遭贸易摩擦[N].北京商报,2007-03-21(002).
[18]吴金慧.我国化学原料药出口为何频遭阻截[N].中国化工报,2006-08-28(005).
[19]度渐成原料药采购主枢纽,制药业规模庞大[EB/OL]中华人民共和国商务部网站http://cccmhpie.mofcom.gov.cn/aarticle/zhongyswhd/201002/20100206771872.html,2010-02-0 2.
[20]印度外包能力得到认可将占市场更大份额[EB/OL]中华人民共和国商务部网站http://cccmhpie.mofcom.gov.cn/aarticle/zhongyswhd/200909/20090906517547.html,2009-09-15.
[21]庾莉萍.我国化学原料药生产与出口形势[J].中国医药技术与市场,2007,(4)：26.
[22]胡霞,黄文龙.出口退税率下调对我国原料药出口的影响及对策分析[J].中国药事,2009,(4)：326.
[23]李玉玲.国外客户质量审计对我国原料药企业出口的影响及对策研究[J].商场现代化,2008,(552)：18-19.
[24]胡霞,康姗姗,赵进.反倾销对我国原料药出口的影响及对策[J].中国药业,2008,(22)：11.
[25]市场分析[J].浙江化工,2006,37(9)：40.
[26]朱捷,田德旺.中国经济可持续发展战略研究[M].北京：中国环境科学出版社,2002.202-235.
[21]Wilson, John S. Technical Barriers to Trade and Trade and Standards, Challenges and Opportunities for Developing Countries. Paper submitted to the Technical Barriers to Trade Committee Meeting, World Trade Organization, Geneva,2000.
[28]叶祖光,苏刚强,邹文俊.欧盟药品市场准入审批程序之述评[J].中国中医药信息杂志,2005, 12 (8)：1.
[29]张旭华.中国医药产品面临的技术性贸易壁垒及应对策略研究[J].中国医药技术经济与管理,2007,1(8)：34.
[30]韩文涛,张铁军.中国原料药国际注册现状[J].河北工业科技,2008,25(3)：163.
[31]官宁云,何春红.国内企业如何应对国际市场监管环境变化[N].中国医药报,2008-11-24(002).
[32]吴惠芳.DMF登记号,进入美国市场的敲门砖[N].中国医药报,2005-03-17(B02).
[33]Guideline for Drug Master Files[EB/OL]美国食品药品监督管理局(FDA)网站http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm122886.htm 2010-03-22.
[34]许铭.中国药企海外征程国际化需破解5大难题[N].医药经济报,2008-10-7.
[35]李瑶,贾岩.兴师?形势?!醒世![N].医药经济报,2010-01-01(A04).
[36]庞然.积极应对原料药出口危机[N].中国医药报,2009-03-26日(B08).
[37]何春,吴伟群,齐雪飞.我国原料药外包的现状与发展对策[J].中国药业,2009,18(20)：10.
[2]伊瑶.2011年全球药品市场将达8800亿美元[N].医药经济报,2010-10-22(A08).
[3]郭晓丹,谈圣采.全球API格局因需求生变[N].医药经济报,2010-01-08(A07).
[4]汤德平,陶锐,项江繁.原料药产业现状和发展趋势[J].上海医药,2007(1)：23.
[5]裘真.我国原料药行业的SWOT分析[J].中国医药技术经济与管理,2008,(1)：38.
[6]谭勇,江沂,金丰杰.中国原料药竞争力对话[N].医药经济报,2003-11-10(A01).
[7]江沂.退税率下调,原料药出口影响有限[N].中国证券报,2007-06-22(B04).
[8]邱家学,李娜.接单外包——中国原料药的新机遇[J].上海医药,2006(10)：446.
[9]马爱霞,韩健.我国原料药出口状况简析[J].昆明理工大学学报(社会科学版),2004,4(4)：2.
[10]曹丽伟.药业产业生产能力国际间转移规律研究[D]：[硕士学位论文].天津：河北工业大学,
[11]. About USP[EB/OL]. http://www.usp.org/aboutUSP/,2010-03-01.
[12]石磊.USP在华设立分支机构,中国原料药出口将获便利[J].上海医药,2007,28(9)：422-423.
[13]朱军.价格战不是主旋律[N].医药经济报,2007-02-28(010).
[14]刘冬冬,孙利华.中印原料药产业竞争力比较研究[J].中国药事,2008,(11)：955.
[15]王承凤.基于节能减排的我国原料药生产企业可持续发展战略研究[D]：[硕士学位论文].沈阳：沈阳药科大学,2008.
[16]顾丽萍,杨潇潇.我国化学原料药的出口前景与对策[J].上海医药,2004,25(1)：15.
[17]赵艳红.我国医药低价出口频遭贸易摩擦[N].北京商报,2007-03-21(002).
[18]吴金慧.我国化学原料药出口为何频遭阻截[N].中国化工报,2006-08-28(005).
[19]度渐成原料药采购主枢纽,制药业规模庞大[EB/OL]中华人民共和国商务部网站http://cccmhpie.mofcom.gov.cn/aarticle/zhongyswhd/201002/20100206771872.html,2010-02-0 2.
[20]印度外包能力得到认可将占市场更大份额[EB/OL]中华人民共和国商务部网站http://cccmhpie.mofcom.gov.cn/aarticle/zhongyswhd/200909/20090906517547.html,2009-09-15.
[21]庾莉萍.我国化学原料药生产与出口形势[J].中国医药技术与市场,2007,(4)：26.
[22]胡霞,黄文龙.出口退税率下调对我国原料药出口的影响及对策分析[J].中国药事,2009,(4)：326.
[23]李玉玲.国外客户质量审计对我国原料药企业出口的影响及对策研究[J].商场现代化,2008,(552)：18-19.
[24]胡霞,康姗姗,赵进.反倾销对我国原料药出口的影响及对策[J].中国药业,2008,(22)：11.
[25]市场分析[J].浙江化工,2006,37(9)：40.
[26]朱捷,田德旺.中国经济可持续发展战略研究[M].北京：中国环境科学出版社,2002.202-235.
[21]Wilson, John S. Technical Barriers to Trade and Trade and Standards, Challenges and Opportunities for Developing Countries. Paper submitted to the Technical Barriers to Trade Committee Meeting, World Trade Organization, Geneva,2000.
[28]叶祖光,苏刚强,邹文俊.欧盟药品市场准入审批程序之述评[J].中国中医药信息杂志,2005, 12 (8)：1.
[29]张旭华.中国医药产品面临的技术性贸易壁垒及应对策略研究[J].中国医药技术经济与管理,2007,1(8)：34.
[30]韩文涛,张铁军.中国原料药国际注册现状[J].河北工业科技,2008,25(3)：163.
[31]官宁云,何春红.国内企业如何应对国际市场监管环境变化[N].中国医药报,2008-11-24(002).
[32]吴惠芳.DMF登记号,进入美国市场的敲门砖[N].中国医药报,2005-03-17(B02).
[33]Guideline for Drug Master Files[EB/OL]美国食品药品监督管理局(FDA)网站http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm122886.htm 2010-03-22.
[34]许铭.中国药企海外征程国际化需破解5大难题[N].医药经济报,2008-10-7.
[35]李瑶,贾岩.兴师?形势?!醒世![N].医药经济报,2010-01-01(A04).
[36]庞然.积极应对原料药出口危机[N].中国医药报,2009-03-26日(B08).
[37]何春,吴伟群,齐雪飞.我国原料药外包的现状与发展对策[J].中国药业,2009,18(20)：10.
© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号 地址：北京市海淀区学院路29号 邮编：100083 电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700 |